{"certainAgreement":{"otherDetails":"MedImmune has 60 days to review results communications prior to public release and may delete information that compromises ongoing studies or is considered proprietary. This restriction is not intended to compromise the objective scientific integrity of the manuscript, it being understood that results shall be published regardless of outcome.","piSponsorEmployee":false,"restrictionType":"OTHER","restrictiveAgreement":true},"limitationsAndCaveats":{"description":"Study enrolment was discontinued after the planned initial interim futility analysis (IA1) due to unlikelihood of achieving statistical significance for OS in the primary endpoint (HPV-unrelated). Therefore, symptoms, function, health-related quality of life (HRQoL), European Organization for Research and Treatment of Cancer (EORTC) scale/item score, pharmacokinetic (PK) parameters, immunogenicity, human leukocyte antigen E (HLA-E), and NKp46+ expression outcomes were not evaluated."},"pointOfContact":{"email":"information.center@astrazeneca.com","organization":"AstraZeneca Clinical Study Information Center","phone":"1-877-240-9479","title":"Global Clinical Lead"}}